Aberdeen Group
ADPT icon

Aberdeen Group’s Adaptive Biotechnologies ADPT Stock Holding History

Aberdeen Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Sell
918,998
-151,629
-14% -$2.32M 0.03% 450
2026
Q1 		$14.9M Buy
1,070,627
+24,117
+2% +$384K 0.02% 499
2025
Q4 		$17M Buy
1,046,510
+52,543
+5% +$858K 0.03% 483
2025
Q3 		$14.9M Sell
993,967
-37,092
-4% -$452K 0.02% 527
2025
Q2 		$12M Sell
1,031,059
-166,563
-14% -$1.51M 0.02% 553
2025
Q1 		$8.9M Buy
1,197,622
+193,563
+19% +$1.49M 0.02% 587
2024
Q4 		$6.02M Sell
1,004,059
-25,388
-2% -$140K 0.01% 617
2024
Q3 		$5.27M Hold
1,029,447
– – 0.01% 639
2024
Q2 		$3.73M Hold
1,029,447
– – 0.01% 681
2024
Q1 		$3.3M Buy
1,029,447
+95,653
+10% +$370K 0.01% 728
2023
Q4 		$4.58M Buy
+933,794
New +$4.26M 0.01% 684

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aberdeen Group's ADPT Position: Q2 2026 in Review

Aberdeen Group reduced its Adaptive Biotechnologies (ADPT) stake by 14% in Q2 2026, selling an estimated $2.32M and leaving 918,998 shares worth $19.7M. The position accounts for 0.03% of the portfolio, ranked #450.

Aberdeen Group first reported a position in ADPT in Q4 2023 and has held it in 11 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Aberdeen Group held 918,998 shares of Adaptive Biotechnologies worth $19.7M as of Q2 2026.
  • Aberdeen Group sold 151,629 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.32M.
  • Adaptive Biotechnologies made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #450 holding.
  • Aberdeen Group first reported a position in Adaptive Biotechnologies in Q4 2023 and has held it in 11 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.